ArticleFrontiers in oncology2024

Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs.

Lin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.